Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

996 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription.
Sigler S, Abdel-Halim M, Fathalla RK, Da Silva LM, Keeton AB, Maxuitenko YY, Berry K, Zhou G, Engel M, Abadi AH, Piazza GA. Sigler S, et al. Among authors: berry k. Anticancer Agents Med Chem. 2024 Sep 2. doi: 10.2174/0118715206318802240821114353. Online ahead of print. Anticancer Agents Med Chem. 2024. PMID: 39225209
Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer.
Borneman RM, Gavin E, Musiyenko A, Richter W, Lee KJ, Crossman DK, Andrews JF, Wilhite AM, McClellan S, Aragon I, Ward AB, Chen X, Keeton AB, Berry K, Piazza GA, Scalici JM, da Silva LM. Borneman RM, et al. Among authors: berry k. J Ovarian Res. 2022 Nov 2;15(1):120. doi: 10.1186/s13048-022-01050-9. J Ovarian Res. 2022. PMID: 36324187 Free PMC article.
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Foote JB, Mattox TE, Keeton AB, Chen X, Smith F, Berry KL, Holmes T, Wang J, Huang CH, Ward AB, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponenko V, Abdelkarim H, Boyd MR, Gorman GS, Manne U, Bae S, El-Rayes BF, Piazza GA. Foote JB, et al. Among authors: berry kl. bioRxiv [Preprint]. 2024 Oct 7:2023.05.17.541233. doi: 10.1101/2023.05.17.541233. bioRxiv. 2024. Update in: Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-0323 PMID: 38328254 Free PMC article. Updated. Preprint.
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma.
Reddy Bandi DS, Nagaraju GP, Sarvesh S, Carstens JL, Foote JB, Graff EC, Fang YD, Keeton AB, Chen X, Berry KL, Bae S, Akce M, Gorman G, Yoon KJ, Manne U, Boyd MR, Buchsbaum DJ, Azmi AS, Maxuitenko YY, Piazza GA, El-Rayes BF. Reddy Bandi DS, et al. bioRxiv [Preprint]. 2024 Oct 8:2024.10.04.616725. doi: 10.1101/2024.10.04.616725. bioRxiv. 2024. PMID: 39416034 Free PMC article. Preprint.
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponeko V, Abdelkarim H, Boyd MR, Gorman G, Manne U, Bae S, El-Rayes BF, Piazza GA. Foote JB, et al. Among authors: berry k. Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-0323. Online ahead of print. Cancer Res. 2024. PMID: 39700396
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
Bajema KL, Yan L, Li Y, Argraves S, Rajeevan N, Fox A, Vergun R, Berry K, Bui D, Huang Y, Lin HM, Hynes DM, Lucero-Obusan C, Schirmer P, Cunningham F, Huang GD, Aslan M, Ioannou GN. Bajema KL, et al. Among authors: berry k. Lancet Infect Dis. 2025 Jan 20:S1473-3099(24)00796-5. doi: 10.1016/S1473-3099(24)00796-5. Online ahead of print. Lancet Infect Dis. 2025. PMID: 39848264
Targeting TRPC channels for control of arthritis-induced bone erosion.
Ray S, McCall JL, Tian JB, Jeon J, Douglas A, Tyler K, Liu S, Berry K, Nicewarner B, Hall C, Groschner K, Bacsa B, Geldenhuys W, Zhu MX, Blair HC, Barnett JB, Soboloff J. Ray S, et al. Among authors: berry k. Sci Adv. 2025 Jan 17;11(3):eabm9843. doi: 10.1126/sciadv.abm9843. Epub 2025 Jan 15. Sci Adv. 2025. PMID: 39813349 Free PMC article.
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
Vutien P, Barnard Giustini A, Kim NJ, Moon AM, Hsu CN, Mezzacappa C, Borgerding JA, Johnson KM, VoPham T, Berry K, Beste LA, Kaplan DE, Taddei TH, Ioannou GN. Vutien P, et al. Among authors: berry k. Hepatology. 2024 Dec 17. doi: 10.1097/HEP.0000000000001183. Online ahead of print. Hepatology. 2024. PMID: 39689352
996 results